These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

9295 related items for PubMed ID: 16708643

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.
    Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.
    Clin Endocrinol (Oxf); 2005 Oct 01; 63(4):461-6. PubMed ID: 16181240
    [Abstract] [Full Text] [Related]

  • 5. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV, Rumiantsev PO, Saenko VA, Il'in AA, Poliakova EIu, Nemtsova MV, Zaletaev DV.
    Mol Biol (Mosk); 2004 Oct 01; 38(4):642-53. PubMed ID: 15456136
    [Abstract] [Full Text] [Related]

  • 6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 7. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M.
    Oncogene; 2003 Jul 17; 22(29):4578-80. PubMed ID: 12881714
    [Abstract] [Full Text] [Related]

  • 8. BRAF mutations in papillary thyroid carcinoma.
    Wojciechowska K, Lewinski A.
    Endocr Regul; 2006 Dec 17; 40(4):129-38. PubMed ID: 17201587
    [Abstract] [Full Text] [Related]

  • 9. BRAF mutations in papillary carcinomas of the thyroid.
    Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S.
    Oncogene; 2003 Sep 25; 22(41):6455-7. PubMed ID: 14508525
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V, Vieira de Castro I, Soares P, Máximo V, Silva P, Magalhães J, Abrosimov A, Guiu XM, Sobrinho-Simões M.
    J Pathol; 2004 Feb 25; 202(2):247-51. PubMed ID: 14743508
    [Abstract] [Full Text] [Related]

  • 12. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.
    J Clin Endocrinol Metab; 2004 May 25; 89(5):2414-20. PubMed ID: 15126572
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 14. BRAF mutation in thyroid cancer.
    Xing M.
    Endocr Relat Cancer; 2005 Jun 15; 12(2):245-62. PubMed ID: 15947100
    [Abstract] [Full Text] [Related]

  • 15. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
    Zhu XL, Zhou XY, Zhu XZ.
    Zhonghua Bing Li Xue Za Zhi; 2005 May 15; 34(5):270-4. PubMed ID: 16181547
    [Abstract] [Full Text] [Related]

  • 16. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 15; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 17. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
    Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K.
    Mol Carcinog; 2007 Mar 15; 46(3):242-8. PubMed ID: 17186541
    [Abstract] [Full Text] [Related]

  • 18. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA.
    Endocrinology; 2006 Feb 15; 147(2):1014-9. PubMed ID: 16254036
    [Abstract] [Full Text] [Related]

  • 19. BRAF mutations in an Italian cohort of thyroid cancers.
    Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P.
    Clin Endocrinol (Oxf); 2004 Aug 15; 61(2):239-43. PubMed ID: 15272920
    [Abstract] [Full Text] [Related]

  • 20. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
    Schmidt J, Derr V, Heinrich MC, Crum CP, Fletcher JA, Corless CL, Nosé V.
    Am J Surg Pathol; 2007 Sep 15; 31(9):1337-43. PubMed ID: 17721188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 465.